公开(公告)号：US20230037294A1

公开(公告)日：2023-02-09

申请号：US17961761

申请日：2022-10-07

Applicant: Memorial Sloan Kettering Cancer Center ,  Cornell University ,  The Curators of the University of Missouri

Inventor： Michelle S. Bradbury ,  Thomas P. Quinn ,  Feng Chen ,  Barney Yoo ,  Jason Lewis ,  Ulrich Wiesner ,  Kai Ma

IPC: A61K47/69 ,  A61K51/12 ,  A61K51/04 ,  A61K51/10 ,  A61K45/06 ,  A61K49/00 ,  A61K49/18 ,  C07K16/40

Abstract: Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attached thereto.

公开(公告)号：US11419952B2

公开(公告)日：2022-08-23

申请号：US16614975

申请日：2018-05-21

Applicant: Cornell University

Inventor： Kai Ma ,  Ulrich B. Wiesner

IPC: A61K49/00 ,  A61K47/69 ,  A61K9/51 ,  A61K47/02 ,  B82Y5/00

Abstract: Described is a versatile surface modification approach to, for example, modularly and orthogonally functionalize nanoparticles (NPs) such as, for example, PEGylated nanoparticles, ith various types of different functional ligands (functional groups) on the NP surface. It enables the synthesis of, for example, penta-functional PEGylated nanoparticles integrating a variety of properties into a single NP, e.g., fluorescence detection, specific cell targeting, radioisotope chelating/labeling, ratiometric pH sensing, and drug delivery, while the overall NP size remains, for example, below 10 nm.

公开(公告)号：US20220118106A1

公开(公告)日：2022-04-21

申请号：US17566015

申请日：2021-12-30

Applicant: Memorial Sloan Kettering Cancer Center ,  Cornell University

Inventor： Michelle S. Bradbury ,  Ulrich Wiesner ,  Michael Overholtzer ,  Howard Scher ,  Kai Ma

IPC: A61K47/69 ,  A61K47/60 ,  A61K38/22

Abstract: Described herein is a method of induced cell death via ferroptosis by nanoparticle ingestion. Moreover, the present disclosure describes the administration of high concentrations of ultrasmall nanoparticles at multiple times over the course of treatment in combination with a nutrient-depleted environment, thereby modulating cellular metabolic pathways to induce cell death by the mechanism ferroptosis. Ferroptosis involves iron, reactive oxygen species, and a synchronous mode of cell death execution.

公开(公告)号：US20190070310A1

公开(公告)日：2019-03-07

申请号：US16137709

申请日：2018-09-21

Applicant: Memorial Sloan Kettering Cancer Center ,  Cornell University

Inventor： Michelle S. Bradbury ,  Barney Yoo ,  Ulrich Wiesner ,  Kai Ma

IPC: A61K47/69 ,  A61K47/60 ,  A61K47/65 ,  A61K31/506 ,  A61K49/00 ,  A61K31/5377 ,  A61K51/12

Abstract: Described herein are nanoparticle drug conjugates (NDCs), which, in certain embodiments, comprise a non-toxic, multi-modality, clinically proven silica-based nanoparticle platform with covalently attached drug molecules/moieties. The nanoparticle drug conjugates (NDCs) demonstrate imaging capability and targeting ligands which efficiently clear through the kidneys. Furthermore, the conjugates incorporate therapeutic agents for cancer detection, prevention, and/or treatment.

公开(公告)号：US20180169264A1

公开(公告)日：2018-06-21

申请号：US15573855

申请日：2016-05-26

Applicant: Memorial Sloan Kettering Cancer Center ,  Cornell University

Inventor： Michelle S. Bradbury ,  Ulrich Wiesner ,  Michael Overholtzer ,  Howard Scher ,  Kai Ma

IPC: A61K47/69 ,  A61K47/60 ,  A61K38/22

Abstract: Described herein is a method of induced cell death via ferroptosis by nanoparticle ingestion. Moreover, the present disclosure describes the administration of high concentrations of ultrasmall nanoparticles at multiple times over the course of treatment in combination with a nutrient-depleted environment, thereby modulating cellular metabolic pathways to induce cell death by the mechanism ferroptosis. Ferroptosis involves iron, reactive oxygen species, and a synchronous mode of cell death execution.

公开(公告)号：US20230201379A1

公开(公告)日：2023-06-29

申请号：US17864671

申请日：2022-07-14

Applicant: CORNELL UNIVERSITY

Inventor： Kai Ma ,  Ulrich B. Wiesner

IPC: A61K49/00 ,  A61K47/69 ,  A61K9/51 ,  A61K47/02 ,  B82Y5/00

CPC classification number: A61K49/0093 ,  A61K47/6923 ,  A61K9/5146 ,  A61K47/02 ,  A61K49/0032 ,  A61K49/0043 ,  A61K49/0054 ,  B82Y5/00

Abstract: Described is a versatile surface modification approach to, for example, modularly and orthogonally functionalize nanoparticles (NPs) such as, for example, PEGylated nanoparticles, ith various types of different functional ligands (functional groups) on the NP surface. It enables the synthesis of, for example, penta-functional PEGylated nanoparticles integrating a variety of properties into a single NP, e.g., fluorescence detection, specific cell targeting, radioisotope chelating/labeling, ratiometric pH sensing, and drug delivery, while the overall NP size remains, for example, below 10 nm.

公开(公告)号：US20220153596A1

公开(公告)日：2022-05-19

申请号：US17459562

申请日：2021-08-27

Applicant: CORNELL UNIVERSITY

Inventor： Melik Z. Turker ,  Thomas C. Gardinier ,  Ulrich B. Wiesner ,  Kai Ma

IPC: C01B33/12 ,  A61K51/12 ,  A61K9/51 ,  A61K33/00 ,  A61K49/00

Abstract: Silica nanorings, methods of making silica nanorings, and uses of silica nanorings. The silica nanorings may be PEGylated. The silica nanorings may be surface functionalized, which may be surface selective functionalization, with one or more polyethylene glycol (PEG) group(s), one or more display group(s), one or more functional group(s), or a combination thereof. The silica nanorings may have a size of 5 to 20 nm. The silica nanorings may be made using micelles. The absence or presence of the micelles during PEGylation and/or functionalization allows for surface selective functionalization. The silica nanorings may be used in various diagnostic and/or treatment methods.

公开(公告)号：US20210030901A1

公开(公告)日：2021-02-04

申请号：US17064352

申请日：2020-10-06

Applicant: Cornell University

Inventor： Ulrich B. Wiesner ,  Melik Z. Turker ,  Kai Ma ,  Tangi Aubert

IPC: A61K51/12 ,  C01B33/18 ,  C09C1/30

Abstract: Provided are inorganic nanocages. The inorganic nanocages may be non-metal nanocages, transition metal oxide nanocages, or transition metal nanocages. Non-metal nanocages may include metal oxides. The inorganic nanocages can be made using micelles formed using pore expander molecules. The inorganic nanocages may be used as catalysts, drug delivery agents, diagnostic agents, therapeutic agents, and theranostic agents.

公开(公告)号：US20190282712A1

公开(公告)日：2019-09-19

申请号：US16463865

申请日：2017-11-29

Applicant: Memorial Sloan Kettering Cancer Center ,  Cornell University ,  The Curators of the University of Missouri

Inventor： Michelle S. Bradbury ,  Thomas P. Quinn ,  Barney Yoo ,  Wolfgang Weber ,  Karim Touijer ,  Howard Scher ,  Kai Ma ,  Ulrich Wiesner

IPC: A61K49/00 ,  A61K51/08 ,  A61K51/12 ,  C07K7/02

Abstract: Described herein are novel conjugates containing an inhibitor (e.g., a PSMA inhibitor, e.g., a gastrin-releasing peptide receptor inhibitor) and metal chelator that are covalently attached to a macromolecule (e.g., a nanoparticle, a polymer, a protein). Such conjugates exhibit distinct properties over the free, unbound inhibitor/chelator construct.

公开(公告)号：US10335501B2

公开(公告)日：2019-07-02

申请号：US14969877

申请日：2015-12-15

Applicant: Memorial Sloan Kettering Cancer Center ,  Cornell University

Inventor： Michelle S. Bradbury ,  Barney Yoo ,  Ulrich Wiesner ,  Peiming Chen ,  Kai Ma ,  Snehal G. Patel ,  Daniella Karassawa Zanoni

IPC: A61B5/00 ,  A61K9/00 ,  A61K49/00

Abstract: Described herein are cyclic peptides, nanoparticles bound with cyclic peptides, and methods for using said cyclic peptides and/or said nanoparticles bound with cyclic peptides for intraoperative nerve tissue imaging.